24/7 Wall St.
Constellation Holds Margin Lead as Vistra Expands With Gas Plants and Buybacks
➖
AI Sentiment
Neutral
5/10
- Home
- MBRX
as of 12-05-2025 3:19pm EST
$7.33
$0.38
-4.93%
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Chart Type:
Time Range:
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 23.5M | IPO Year: | 2016 |
| Target Price: | $125.00 | AVG Volume (30 days): | 105.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -76.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.01 - $91.25 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered MBRX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 74.24%
74.24%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Moleculin Biotech Inc. News
MBRX Breaking Stock News: Dive into MBRX Ticker-Specific Updates for Smart Investing
24/7 Wall St.
Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue
➖
AI Sentiment
Neutral
5/10
Motley Fool
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
📊
AI Sentiment
Positive
7/10
24/7 Wall St.
CoreWeave Hits Profitability While Applied Digital Burns Cash Building Data Centers
➖
AI Sentiment
Neutral
5/10
USA TODAY
Arizona congresswoman says she was pepper-sprayed during ICE protest
➖
AI Sentiment
Neutral
4/10
PR Newswire
Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
📈
AI Sentiment
Highly Positive
8/10
Compare MBRX vs Leading Stocks
See how MBRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MBRX Moleculin Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.